Filtered By:
Specialty: Cardiology
Drug: Hydrochlorothiazide

This page shows you your search results in order of date.

Order by Relevance | Date

Total 19 results found since Jan 2013.

A cardiovascular polypill for secondary stroke prevention in a tertiary centre in Ghana (SMAART): a phase 2 randomised clinical trial
Lancet Glob Health. 2023 Oct;11(10):e1619-e1628. doi: 10.1016/S2214-109X(23)00347-9.ABSTRACTBACKGROUND: A cardiovascular polypill containing generic drugs might facilitate sustained implementation of and adherence to evidence-based treatments, especially in resource-limited settings. However, the impact of a cardiovascular polypill in mitigating atherosclerotic risk among stroke survivors has not been assessed. We aimed to compare a polypill regimen with usual care on carotid intima-media thickness (CIMT) regression after ischaemic stroke.METHODS: In SMAART, a phase 2 parallel, open-label, assessor-masked, randomised clini...
Source: Atherosclerosis - September 21, 2023 Category: Cardiology Authors: Fred Stephen Sarfo Jenifer Voeks Sheila Adamu Benedict Apaw Agyei Manolo Agbenorku Nyantakyi Adu-Darko Mercy Adomah Oteng Vida Obese Rexford Adu Gyamfi Nathaniel Adusei Mensah Raelle Tagge Michael Ampofo Samuel Amoabeng Kontoh Samuel Blay Nguah Bruce Ovbi Source Type: research

Chlorthalidone versus hydrochlorothiazide for preventing cardiovascular disease in hypertension: Is the case closed?
Hellenic J Cardiol. 2023 Jul 8:S1109-9666(23)00115-X. doi: 10.1016/j.hjc.2023.07.003. Online ahead of print.ABSTRACTThe optimal diuretic choice [hydrochlorothiazide (HCTZ) or chlorthalidone (CTD)] for the management of hypertension has been an ongoing debate for several years. HCTZ is widely used in the form of single-pill combinations, whereas CTD is a more potent drug vs. HCTZ, especially in reducing nighttime blood pressure (BP), with some indirect evidence suggesting a superiority in terms of cardiovascular (CV) risk reduction. In addition, recent data showed that CTD was safe and effective in terms of BP lowering in p...
Source: Hellenic Journal of Cardiology - July 10, 2023 Category: Cardiology Authors: Anastasios Kollias Konstantinos G Kyriakoulis George S Stergiou Source Type: research

Network meta-analysis of efficacy and safety of chlorthalidone and hydrochlorothiazide in hypertensive patients
Hypertension is a chronic condition leading to increased stress on the heart and blood vessels, a critical risk factor for clinically significant events such as myocardial infarction heart failure, stroke and death. Chlorthalidone and hydrochlorothiazide are first-line antihypertensive agents for most patients with hypertension. The aim of our meta-analysis was to compare the efficacy and safety of both therapies in patients with hypertension. Searches of electronic databases PubMed, MEDLINE, Scopus, PsycInfo and eLIBRARY.ru, were performed. We used network meta-analysis to combine direct and indirect evidence. Forest plot...
Source: Blood Pressure Monitoring - March 11, 2021 Category: Cardiology Tags: Review Article Source Type: research

Cardiovascular Benefits of Angiotensin Converting Enzyme Inhibition plus Calcium Channel Blockade in Patients Achieving Tight Blood Pressure Control and with Resistant Hypertension.
CONCLUSIONS: Combination therapy adding a calcium channel blocker, rather than hydrochlorothiazide, to an angiotensin converting enzyme inhibitor was more effective in preventing composite cardiovascular events even in hypertensive patients achieving aggressive systolic blood pressure targets as well as in those with apparent resistant hypertension. Our findings add support that most patients, including those following contemporary clinical guidelines, will benefit from this combination. TRIAL REGISTRATION: ClinicalTrials.gov, NCT00170950. PMID: 33216879 [PubMed - as supplied by publisher]
Source: American Journal of Hypertension - November 20, 2020 Category: Cardiology Authors: Brook RD, Kaciroti N, Bakris G, Dahlöf B, Pitt B, Velazquez E, Weber MA, Jamerson KA, ACCOMPLISH investigators Tags: Am J Hypertens Source Type: research

Personalised Single-Pill Combination Therapy in Hypertensive Patients: An Update of a Practical Treatment Platform
AbstractDespite the improvements in the management of hypertension during the last three decades, it continues to be one of the leading causes of cardiovascular morbidity and mortality worldwide. Effective and sustained reductions in blood pressure (BP) reduce the incidence of myocardial infarction, stroke, congestive heart failure and cardiovascular death. However, the proportion of patients who achieve the recommended BP goal (<  140/90 mmHg) is persistently low, worldwide. Poor adherence to therapy, complex therapeutic regimens, clinical inertia, drug-related adverse events and multiple risk factors or comorbiditie...
Source: High Blood Pressure and Cardiovascular Prevention - October 31, 2017 Category: Cardiology Source Type: research

Triple Combination Therapies Based on Olmesartan: A Personalized Therapeutic Approach to Improve Blood Pressure Control
AbstractRecent epidemiological surveys have demonstrated that effective and sustained blood pressure (BP) control is achieved in a relatively small proportion of treated hypertensive patients. Indeed, treatment of hypertension represents a key strategy for preventing coronary artery disease, stroke, congestive heart failure and cardiovascular death. Several interventions have been proposed by international guidelines for ameliorating hypertension management and control, mostly including integrated and multi-dimensional pharmacological and non-pharmacological strategies. In particular, numerous evidence demonstrated that a ...
Source: High Blood Pressure and Cardiovascular Prevention - June 12, 2017 Category: Cardiology Source Type: research

All diuretics used in the treatment of hypertension are not the same.
Abstract Diuretics have been used for years to treat hypertension as both a monotherapy and in combination. Hydrochlorothiazide, indapamide, and chlorthalidone have frequently been considered in the same category as thiazide diuretics, but there is no evidence that their activities are similar. Studies have shown that chlorthalidone and indapamide reduce cardiovascular morbidity and mortality; however, there is no study indicating that hydrochlorothiazide has beneficial effects on cardiovascular outcomes such as myocardial infarction, renal failure, stroke, or death. Hydrochlorothiazide has less effect on blood pr...
Source: Turk Kardiyoloji Dernegi arsivi - December 31, 2016 Category: Cardiology Authors: Asil S, Atalar E Tags: Turk Kardiyol Dern Ars Source Type: research

Changes in selected metabolic parameters in patients over 65 receiving hydrochlorothiazide plus amiloride, atenolol or placebo in the MRC elderly trial
Treatment of hypertension reduces incidence of stroke, myocardial infarction and heart failure perhaps partly by controlling different metabolic parameters. There is limited information regarding the changes i...
Source: BMC Cardiovascular Disorders - October 4, 2016 Category: Cardiology Authors: Damian J. Damian, Roseanne McNamee and Matthew Carr Source Type: research

Safety and Efficacy of Losartan/Hydrochlorothiazide Combination in Elderly Patients with Morning Hypertension: Mappy Study
Background: Cardiovascular events, such as stroke and myocardial infarction, occur most frequently in the morning. Morning hypertension is characteristic feature of hypertension in the elderly, and is attributed to hypertensive organ damage and cardiovascular events. However, treatment of morning hypertension has not been established, especially in the elderly patients. The aim of this study was to compare the safety and effectiveness between an an angiotensin II receptor blocker (ARB) / hydrochlorothiazide (HCTZ) combination therapy and high-dose ARB therapy in the elderly (75 years or more) and younger (less than 75 years) patients.
Source: Journal of Cardiac Failure - August 24, 2016 Category: Cardiology Authors: Hiroki Uchiwa, Hisashi Kai, Yoshiko Iwamoto, Takahiro Anegawa, Kenji Fukuda, Tsutomu Imaizumi, Yoshihiro Fukumoto Source Type: research

Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics
Conclusions The HOPE-3 trial will provide new information on cholesterol and BP lowering in intermediate-risk populations with average cholesterol and BP levels and is expected to inform approaches to primary prevention worldwide (HOPE-3 ClinicalTrials.gov NCT00468923).
Source: Canadian Journal of Cardiology - February 25, 2016 Category: Cardiology Source Type: research

Polypill for the prevention of cardiovascular disease (PolyIran): study design and rationale for a pragmatic cluster randomized controlled trial
Conclusion The infrastructure of GCS and the primary health care system in Iran enabled the conduct of this pragmatic large-scale trial. If the polypill strategy proves effective, it may be implemented to prevent cardiovascular disease in developing countries.
Source: European Journal of Preventive Cardiology - November 9, 2015 Category: Cardiology Authors: Ostovaneh, M. R., Poustchi, H., Hemming, K., Marjani, H., Pourshams, A., Nateghi, A., Majed, M., Navabakhsh, B., Khoshnia, M., Jaafari, E., Mohammadifard, N., Malekzadeh, F., Merat, S., Sadeghi, M., Naemi, M., Etemadi, A., Thomas, G. N., Sarrafzadegan, N. Tags: Original scientific paper Source Type: research

Trends in Antihypertensive Medication Use and Blood Pressure Control Among Adults With Hypertension in Germany.
CONCLUSIONS: Increased and improved antihypertensive use might be a main contributor to the decrease in BP observed in Germany in the last decade. However, there are still socio-demographic and health disparities in hypertension treatment and control. PMID: 25968124 [PubMed - as supplied by publisher]
Source: American Journal of Hypertension - May 11, 2015 Category: Cardiology Authors: Sarganas G, Knopf H, Grams D, Neuhauser HK Tags: Am J Hypertens Source Type: research

Amlodipine+Benazepril is Superior to Hydrochlorothiazide+Benazepril Irrespective of Baseline Pulse Pressure: Subanalysis of the ACCOMPLISH Trial
Pulse pressure (PP) is an independent risk factor for cardiovascular (CV) disease and death but few studies have investigated the effect of antihypertensive treatments in relation to PP levels before treatment. The Avoiding Cardiovascular Events Through Combination Therapy in Patients Living With Systolic Hypertension (ACCOMPLISH) trial showed that the combination of benazepril+amlodipine (B+A) is superior to benazepril+hydrochlorothiazide (B+H) in reducing CV events. We aimed to investigate whether the treatment effects in the ACCOMPLISH trial were dependent on baseline PP. High‐risk hypertensive patients (n=11,499) wer...
Source: The Journal of Clinical Hypertension - December 22, 2014 Category: Cardiology Authors: Per H. Skoglund, Per Svensson, Joline Asp, Björn Dahlöf, Sverre E. Kjeldsen, Kenneth A. Jamerson, Michael A. Weber, Yan Jia, Dion H. Zappe, Jan Östergren, Tags: Original Paper Source Type: research

Critical Blood Pressure Threshold Dependence of Hypertensive Injury and Repair in a Malignant Nephrosclerosis Model Kidney
Most patients with essential hypertension do not exhibit substantial renal damage. Renal autoregulation by preventing glomerular transmission of systemic pressures has been postulated to mediate this resistance. Conversely, malignant nephrosclerosis (MN) has been postulated to develop when severe hypertension exceeds a critical ceiling. If the concept is valid, even modest blood pressure (BP) reductions to below this threshold regardless of antihypertensive class (1) should prevent MN and (2) lead to the healing of the already developed MN lesions. Both predicates were tested using BP radiotelemetry in the stroke-prone spo...
Source: Hypertension - September 10, 2014 Category: Cardiology Authors: Griffin, K. A., Polichnowski, A., Litbarg, N., Picken, M., Venkatachalam, M. A., Bidani, A. K. Tags: Animal models of human disease Kidney Source Type: research